Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial.
Raffaele PiccoloMarisa AvvedimentoMario Enrico CanonicoPaola GargiuloRoberta PaolilloValeria ContiFabrizio Dal PiazAmelia FilippelliCarmine MoriscoFiorenzo SimonettiAttilio LeoneAlessandra MarennaDario BruzzeseGiuseppe GargiuloEugenio StabileLuigi Di SerafinoAnna FranzonePlinio CirilloGiovanni EspositoPublished in: Cardiovascular drugs and therapy (2022)
The PLINY THE ELDER trial will determine whether a lower dose of ticagrelor confers non-inferior platelet inhibition compared with the standard dose in the early phase of ACS among elderly patients undergoing PCI, informing future clinical investigation.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- antiplatelet therapy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- patients undergoing
- phase iii
- study protocol
- middle aged
- phase ii
- clinical trial
- community dwelling
- coronary artery disease
- acute myocardial infarction
- physical activity
- coronary artery bypass grafting
- open label
- randomized controlled trial
- heart failure
- atrial fibrillation
- coronary artery bypass